Cellectis Outlines Plan to Enhance Eti-cel Efficacy in Lymphoma Patients
Biotechnology company Cellectis presented updated results and a development plan for its experimental cancer therapy, eti-cel. A new treatment cohort incorporating IL-2 support is set to begin enrollment in early 2026.
New York-based clinical-stage biotechnology company Cellectis announced updated data and a development plan for its experimental cancer therapy, eti-cel, at the 67th Annual Meeting of the American Society of Hematology (ASH) on December 8, 2025.
Preliminary results from the Phase 1 NATHALI-01 clinical trial showed that eti-cel, a dual CAR-T targeting CD20 and CD22, achieved an 88% overall response rate (ORR) and a 63% complete response rate (CR) in eight patients with relapsed/refractory non-Hodgkin lymphoma (r/r NHL) after at least two prior lines of therapy.
Additionally, in vivo data suggest that low-dose Interleukin-2 (IL-2) support may enhance CAR-T cell expansion and persistence, potentially boosting efficacy without increasing toxicity. Cellectis plans to investigate this approach further.
The company will begin enrolling patients into an IL-2 support cohort in the first quarter of 2026. Full Phase 1 dataset results are anticipated in 2026. Cellectis believes this strategy could improve outcomes for patients with difficult-to-treat lymphomas.